Published in Cancer Res on October 01, 1997
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol (2000) 3.42
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A (1999) 3.10
Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev (1999) 2.87
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
Pten, a protean tumor suppressor. Am J Pathol (2001) 2.42
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 2.06
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol (2011) 2.00
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal (2010) 1.94
PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A (2008) 1.92
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am J Pathol (1998) 1.67
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer (1999) 1.54
Germline PTEN mutations in Cowden syndrome-like families. J Med Genet (1998) 1.51
Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J Cell Biol (2009) 1.51
The pathobiology of glioma tumors. Annu Rev Pathol (2010) 1.40
PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol (2009) 1.36
p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol (2009) 1.36
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol (1999) 1.26
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol (2008) 1.22
Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol (2009) 1.21
Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene (2009) 1.18
Aneuploidy and tumorigenesis. Semin Cell Dev Biol (2011) 1.15
The microRNA-148/152 family: multi-faceted players. Mol Cancer (2013) 1.14
Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Mol Cell Biol (2011) 1.11
Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol (1999) 1.11
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol (2014) 1.06
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol (2001) 1.04
Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J (2013) 1.03
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch (2003) 1.03
Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol (2012) 1.02
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther (2012) 0.97
Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer (1999) 0.96
Functionally enigmatic genes: a case study of the brain ignorome. PLoS One (2014) 0.96
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther (2009) 0.95
PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res (2001) 0.94
Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am (2013) 0.94
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun (2015) 0.92
Role of receptor tyrosine kinases and their ligands in glioblastoma. Cells (2014) 0.91
Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia (2005) 0.91
Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol (1999) 0.90
Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol (2010) 0.89
Studying a complex tumor: potential and pitfalls. Cancer J (2012) 0.87
MicroRNA in Human Glioma. Cancers (Basel) (2013) 0.87
The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) (2015) 0.84
Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer (2012) 0.84
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy. World J Surg Oncol (2013) 0.84
The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res (2012) 0.83
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep (2015) 0.82
Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer (2001) 0.82
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol (2011) 0.82
Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field. Biomark Insights (2007) 0.82
PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition. Mol Cancer Res (2014) 0.82
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro Oncol (2011) 0.81
PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons. J Neurovirol (2011) 0.81
High grade glioblastoma is associated with aberrant expression of ZFP57, a protein involved in gene imprinting, and of CPT1A and CPT1C that regulate fatty acid metabolism. Cancer Biol Ther (2014) 0.81
Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells. World J Gastroenterol (2013) 0.81
Involvement of estrogen receptor β5 in the progression of glioma. Brain Res (2013) 0.81
Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg Focus (2014) 0.81
Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer (1999) 0.81
Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer. Nutr Res Pract (2013) 0.80
Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome. Eur J Med Res (2014) 0.80
PTEN transcript variants caused by illegitimate splicing in "aged" blood samples and EBV-transformed cell lines. Hum Genet (2010) 0.80
Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling. Cancer Res (2015) 0.79
Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) (2016) 0.79
Chromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme. Mol Neurobiol (2014) 0.79
Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity. Cancer Res (2013) 0.79
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2011) 0.78
Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies? Stem Cell Investig (2016) 0.77
Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients. J Clin Med (2015) 0.77
Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J Gastroenterol (2005) 0.77
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. Int J Mol Sci (2017) 0.76
RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Anticancer Drugs (2016) 0.76
Investigation of MMAC/PTEN gene mutations and protein expression in low grade gliomas. Cell Mol Neurobiol (2009) 0.76
A PTEN translational isoform has PTEN-like activity. Chin J Cancer Res (2015) 0.75
Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma. Mol Cytogenet (2015) 0.75
Significance of p85 expression as a prognostic factor for patients with breast cancer. Oncol Lett (2014) 0.75
What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia. Malays J Med Sci (2004) 0.75
Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours. Br J Cancer (1999) 0.75
Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer. Proteins (2016) 0.75
Developing a Novel Embryo-Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics. Zebrafish (2016) 0.75
Netrin-1 promotes glioma growth by activating NF-κB via UNC5A. Sci Rep (2017) 0.75
PTEN Gene Induces Cell Invasion and Migration via Regulating AKT/GSK-3β/β-Catenin Signaling Pathway in Human Gastric Cancer. Dig Dis Sci (2017) 0.75
Effect of operating room care combined with home care for the postoperative rehabilitation and prognosis of gastric cancer patients with low PTEN gene expression. Oncol Lett (2017) 0.75
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02
p53 mutations in human cancers. Science (1991) 31.96
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Comparative genomics of the eukaryotes. Science (2000) 26.62
Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast (1998) 23.00
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89
Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet (1999) 11.10
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
Crystal structure of the RNA-binding domain of the U1 small nuclear ribonucleoprotein A. Nature (1990) 7.32
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 6.62
IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity (2001) 6.56
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Sonic hedgehog signaling is essential for hair development. Curr Biol (1998) 5.58
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science (1999) 5.22
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A (2001) 4.62
Crystal structures of two Sm protein complexes and their implications for the assembly of the spliceosomal snRNPs. Cell (1999) 4.57
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Connexins regulate calcium signaling by controlling ATP release. Proc Natl Acad Sci U S A (1998) 4.35
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res (1997) 4.32
Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. EMBO J (2001) 4.23
A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell (1998) 4.21
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother (2011) 4.21
Dominance is the major genetic basis of heterosis in rice as revealed by QTL analysis using molecular markers. Genetics (1995) 4.18
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science (1997) 4.03
Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest (1997) 4.00
Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol (2003) 3.93
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology (1998) 3.79
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Brassinosteroid-insensitive-1 is a ubiquitously expressed leucine-rich repeat receptor serine/threonine kinase. Plant Physiol (2000) 3.73
Conformation and function of the N-linked glycan in the adhesion domain of human CD2. Science (1995) 3.62
Suicide within 12 months of contact with mental health services: national clinical survey. BMJ (1999) 3.61
Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem (2001) 3.60
Light control of Arabidopsis development entails coordinated regulation of genome expression and cellular pathways. Plant Cell (2001) 3.60
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
PTEN: life as a tumor suppressor. Exp Cell Res (2001) 3.41
LifeLines: using visualization to enhance navigation and analysis of patient records. Proc AMIA Symp (1998) 3.35
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther (2014) 3.32
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Mutations of GTBP in genetically unstable cells. Science (1995) 3.23
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin. Neuron (2001) 3.20
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly. N Engl J Med (1998) 3.13
Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13
Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol (1991) 3.09
Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychol Med (2010) 3.08
Perception of brassinosteroids by the extracellular domain of the receptor kinase BRI1. Science (2000) 3.07
Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med (1995) 3.07
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03
Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. J Pediatr (2000) 3.02
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
The Arabidopsis deetiolated2 mutant is blocked early in brassinosteroid biosynthesis. Plant Cell (1997) 3.00
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Artificial 'spin ice' in a geometrically frustrated lattice of nanoscale ferromagnetic islands. Nature (2006) 2.96
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93